MORANDI, ANDREA
 Distribuzione geografica
Continente #
NA - Nord America 4.499
EU - Europa 3.478
AS - Asia 2.411
SA - Sud America 334
AF - Africa 61
OC - Oceania 18
Continente sconosciuto - Info sul continente non disponibili 1
Totale 10.802
Nazione #
US - Stati Uniti d'America 4.428
PL - Polonia 1.045
RU - Federazione Russa 890
IT - Italia 782
SG - Singapore 711
CN - Cina 619
HK - Hong Kong 334
BR - Brasile 259
VN - Vietnam 247
KR - Corea 177
IE - Irlanda 157
SE - Svezia 143
FR - Francia 100
FI - Finlandia 99
BD - Bangladesh 98
DE - Germania 76
IN - India 51
GB - Regno Unito 45
ID - Indonesia 39
CA - Canada 38
ES - Italia 37
NL - Olanda 35
JO - Giordania 28
AR - Argentina 27
EC - Ecuador 19
UA - Ucraina 18
AU - Australia 17
JP - Giappone 16
CH - Svizzera 14
IQ - Iraq 14
MX - Messico 14
TR - Turchia 14
ZA - Sudafrica 14
BE - Belgio 11
CI - Costa d'Avorio 11
AE - Emirati Arabi Uniti 10
PK - Pakistan 9
CO - Colombia 8
NG - Nigeria 8
MA - Marocco 7
MY - Malesia 7
TW - Taiwan 7
CL - Cile 6
AT - Austria 5
AZ - Azerbaigian 5
GR - Grecia 5
UY - Uruguay 5
BJ - Benin 4
CR - Costa Rica 4
DZ - Algeria 4
EG - Egitto 4
PY - Paraguay 4
TT - Trinidad e Tobago 4
VE - Venezuela 4
AL - Albania 3
IL - Israele 3
KE - Kenya 3
PA - Panama 3
SA - Arabia Saudita 3
BG - Bulgaria 2
CZ - Repubblica Ceca 2
DK - Danimarca 2
GT - Guatemala 2
JM - Giamaica 2
KW - Kuwait 2
KZ - Kazakistan 2
LB - Libano 2
NI - Nicaragua 2
NP - Nepal 2
PH - Filippine 2
PT - Portogallo 2
RO - Romania 2
SN - Senegal 2
TH - Thailandia 2
TN - Tunisia 2
UZ - Uzbekistan 2
AO - Angola 1
BO - Bolivia 1
CY - Cipro 1
EU - Europa 1
GL - Groenlandia 1
KG - Kirghizistan 1
KI - Kiribati 1
LT - Lituania 1
LV - Lettonia 1
MM - Myanmar 1
PE - Perù 1
PR - Porto Rico 1
PS - Palestinian Territory 1
QA - Qatar 1
SK - Slovacchia (Repubblica Slovacca) 1
ZW - Zimbabwe 1
Totale 10.802
Città #
Warsaw 1.040
Santa Clara 847
Ashburn 622
Singapore 546
Fairfield 453
Hong Kong 295
San Jose 200
Woodbridge 198
Seattle 189
Houston 187
Seoul 170
Cambridge 166
Dublin 156
Florence 142
Hefei 138
Chandler 134
Wilmington 129
Beijing 126
Milan 113
Ann Arbor 90
Ho Chi Minh City 83
Altamura 69
Lawrence 69
Helsinki 65
Council Bluffs 59
Los Angeles 56
Lauterbourg 49
Buffalo 47
Hanoi 44
Princeton 43
Rome 42
The Dalles 42
São Paulo 35
Jakarta 34
New York 34
Moscow 32
Shanghai 31
Medford 30
Paris 28
Dong Ket 27
Clifton 26
San Diego 26
Kent 25
Mumbai 23
Munich 23
Dallas 22
Boston 21
Frankfurt am Main 20
Barcelona 18
Boardman 18
Melbourne 17
Naples 17
Phoenix 17
Tokyo 15
Turin 15
Chicago 13
Da Nang 13
Lappeenranta 13
London 13
Orem 13
Bern 12
Falls Church 12
Abidjan 11
Brooklyn 11
Brussels 11
Tianjin 11
Bologna 10
Jacksonville 10
Belo Horizonte 9
Redondo Beach 9
Toronto 9
Yubileyny 9
Amman 8
Brasília 8
Chieri 8
Hangzhou 8
Turku 8
Abuja 7
Baghdad 7
Bengaluru 7
Guangzhou 7
Johannesburg 7
Padua 7
Quito 7
Stockholm 7
Can Tho 6
Denver 6
Donostia / San Sebastian 6
Guayaquil 6
Hải Dương 6
Istanbul 6
Miano 6
Montreal 6
Nuremberg 6
Ribeirão Preto 6
San Francisco 6
St Louis 6
Amsterdam 5
Baku 5
Genoa 5
Totale 7.535
Nome #
The Colony-Stimulating Factor-1 (CSF-1) Receptor Sustains ERK1/2 Activation and Proliferation in Breast Cancer Cell Lines. 376
Zoledronic acid impairs stromal reactivity by inhibiting M2-macrophages polarization and prostate cancer-associated fibroblasts. 360
Chromatin-associated CSF-1R binds to the promoter of proliferation-related genes in breast cancer cells. 343
Metabolic shift toward oxidative phosphorylation in docetaxel resistant prostate cancer cells. 336
Reprogramming of Amino Acid Transporters to Support Aspartate and Glutamate Dependency Sustains Endocrine Resistance in Breast Cancer 318
The metabolic gene HAO2 is downregulated in hepatocellular carcinoma and predicts metastasis and poor survival 299
Mesenchymal to amoeboid transition is associated with stem-like features of melanoma cells 291
Targeting stromal-induced pyruvate kinase M2 nuclear translocation impairs OXPHOS and prostate cancer metastatic spread 267
Cancer-associated fibroblasts promote prostate cancer malignancy via metabolic rewiring and mitochondrial transfer 267
Glucose Metabolic Reprogramming of ER Breast Cancer in Acquired Resistance to the CDK4/6 Inhibitor Palbociclib 262
Compartmentalized activities of the pyruvate dehydrogenase complex sustain lipogenesis in prostate cancer 253
Targeting the receptor tyrosine kinase RET in combination with aromatase inhibitors in ER positive breast cancer xenografts 233
Down-Regulation of SOX2 Underlies the Inhibitory Effects of the Triphenylmethane Gentian Violet on Melanoma Cell Self-Renewal and Survival 228
Lactate modulates CD4 + T-cell polarization and induces an immunosuppressive environment, which sustains prostate carcinoma progression via TLR8/miR21 axis 221
Metabolic reprogramming identifies the most aggressive lesions at early phases of hepatic carcinogenesis 213
Fat and Furious: Lipid Metabolism in Antitumoral Therapy Response and Resistance 210
Stromal-induced downregulation of miR-1247 promotes prostate cancer malignancy 208
miR-155 Drives Metabolic Reprogramming of ER+ Breast Cancer Cells Following Long-Term Estrogen Deprivation and Predicts Clinical Response to Aromatase Inhibitors. 205
Selective anti-leukaemic activity of low-dose histone deacetylase inhibitor ITF2357 on AML1/ETO-positive cells 202
Targeting the Metabolic Reprogramming That Controls Epithelial-to-Mesenchymal Transition in Aggressive Tumors 199
Lactate supports cell-autonomous ECM production to sustain metastatic behavior in prostate cancer 194
Senescent stroma promotes prostate cancer progression: The role of miR-210 190
Signaling pathways regulating redox balance in cancer metabolism 187
ERK5/BMK1 is indispensable for optimal colony-stimulating factor 1 (CSF-1)-induced proliferation in macrophages in a Src-dependent fashion. 182
Lactate: A Metabolic Driver in the Tumour Landscape 181
Linking metabolic reprogramming to therapy resistance in cancer 181
Acetyl-CoA carboxylase 1 controls a lipid droplet-peroxisome axis and is a vulnerability of endocrine-resistant ER+ breast cancer 179
Integrating radiation therapy with targeted treatments for breast cancer: From bench to bedside 177
International multidisciplinary consensus on the integration of radiotherapy with new systemic treatments for breast cancer: European Society for Radiotherapy and Oncology (ESTRO)-endorsed recommendations 176
Metabolic reprogramming in Nrf2-driven proliferation of normal rat hepatocytes 171
Lysosomal lipid switch sensitises to nutrient deprivation and mTOR targeting in pancreatic cancer 169
FADS1/2 control lipid metabolism and ferroptosis susceptibility in triple-negative breast cancer 166
Succinate dehydrogenase subunit B mutations modify human neuroblastoma cell metabolism and proliferation 162
Safety of CDK4/6 inhibitors and concomitant radiation therapy in patients affected by metastatic breast cancer 159
Lactate rewires lipid metabolism and sustains a metabolic-epigenetic axis in prostate cancer 159
Focal adhesion kinase (FAK) binds RET kinase via its FERM domain, priming a direct and reciprocal RET-FAK transactivation mechanism 158
Targeting RET-interleukin-6 crosstalk to impair metastatic dissemination in breast cancer 157
Essential requirements for reporting radiation therapy in breast cancer clinical trials: An international multi-disciplinary consensus endorsed by the European Society for Radiotherapy and Oncology (ESTRO) 156
Sex difference in liver diseases: How preclinical models help to dissect the sex-related mechanisms sustaining NAFLD and hepatocellular carcinoma 156
Safety profile of trastuzumab-emtansine (T-DM1) with concurrent radiation therapy: a systematic review and meta-analysis 155
GDNF-RET signaling in ER-positive breast cancers is a key determinant of response and resistance to aromatase inhibitors 155
Expression of activated VEGFR2 by R1051Q mutation alters the energy metabolism of Sk-Mel-31 melanoma cells by increasing glutamine dependence 155
RET in breast cancer: functional and therapeutic implications 154
Metabolic implication of tumor:stroma crosstalk in breast cancer. 154
Thyroid hormone inhibits hepatocellular carcinoma progression via induction of differentiation and metabolic reprogramming 148
Nutrient Exploitation within the Tumor–Stroma Metabolic Crosstalk 147
In vivo imaging of the spatial heterogeneity of intratumoral acidosis (pH) as a marker of the metastatic phenotype in breast cancer 138
A novel phage display based platform for exosome diversity characterization 134
CD44 and SLC1A2 are commonly regulated but do not form a fusion transcript in ER+ breast cancer 121
Ponatinib is a potent inhibitor of wild-type and drug-resistant gatekeeper mutant RET kinase 121
Oxidative phosphorylation is a metabolic vulnerability of endocrine therapy and palbociclib resistant metastatic breast cancers 120
Targeting the receptor tyrosine kinase RET sensitizes breast cancer cells to tamoxifen treatment and reveals a role for RET in endocrine resistance 109
Safety profile of cyclin-dependent kinase (CDK) 4/6 inhibitors with concurrent radiation therapy: A systematic review and meta-analysis 95
Cardioprotection in patients with anthracycline-treated breast cancer: final analysis from the 2 × 2 randomized, placebo-controlled, double-blind SAFE trial 91
Estrogen-dependent activation of TRX2 reverses oxidative stress and metabolic dysfunction associated with steatotic disease 89
MAPK15 controls intracellular lipid uptake and protects mammalian liver from steatotic disease 65
ESR1 Activating Mutations Confer Metabolic Vulnerabilities in ER+ Breast Cancer 59
Targeting carbonic anhydrase IX/XII prevents the anti-ferroptotic effect of stromal lactic acid in prostate carcinoma 54
Lead induces cell-autonomous proliferation and metabolic reprogramming of hepatocytes 47
Sub-lethal concentrations of Aβ oligomers and glutamate induce ROS formation largely by calcium-mediated activation of the NADPH oxidase 42
Under pressure: peroxisomes in cancer therapy resistance 7
Cell Cycle Control of Nuclear Metabolism Couples Phosphatidylinositol Signaling to Histone Methylation 7
Totale 10.918
Categoria #
all - tutte 28.809
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 28.809


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022396 13 69 36 14 20 11 20 42 11 32 40 88
2022/2023778 62 190 44 41 49 137 96 35 69 9 27 19
2023/2024402 16 35 49 15 31 23 20 102 28 22 31 30
2024/20252.606 84 234 153 383 695 365 64 191 111 76 100 150
2025/20263.807 343 446 354 359 450 131 474 184 201 262 194 409
2026/2027115 115 0 0 0 0 0 0 0 0 0 0 0
Totale 10.918